Cytopia Announces Novel Anti-Cancer Drug Development Collaboration
News May 13, 2008
Cytopia Limited has entered into an anti-cancer drug discovery and development collaboration with Cancer Therapeutics CRC Pty Ltd. This agreement leverages Cytopia's early stage drug discovery pipeline of kinase inhibitors, a class of targeted therapeutics that is one of the fastest growing segments of the cancer drug market.
Cytopia will retain an option over exclusive commercialization rights for any drug candidates delivered by the collaboration. Should Cytopia choose not to exercise this option, Cancer Therapeutics may proceed with commercialization activities. In the event that all milestones to registration are successfully achieved, both Cancer Therapeutics and Cytopia will share in any partnering revenues, as well as royalty payments from a marketed drug.
Andrew Macdonald, CEO of Cytopia said, "Cytopia's drug discovery engine has generated many opportunities for novel cancer therapies and this innovative partnership gives us the freedom to focus investment on our later stage pipeline while still allowing our very early pipeline to move forward."
"Most importantly, the agreement leaves us with an option to capture the value upside for our investors if a new cancer drug is taken to market."
Under the terms of the collaboration, Cytopia has out-licensed specific proprietary technology to Cancer Therapeutics for an undisclosed kinase enzyme target with potential for treating metastatic cancers. Development of an inhibitor of this particular kinase could have blockbuster potential in the cancer market.
Under the project plan, Cancer Therapeutics will conduct and fund further development of the Cytopia compounds for at least two years. Cancer Therapeutics is a company, formed under the Australian Commonwealth Government's CRC scheme, to discover and develop new cancer drugs from Australia's research base. It will undertake responsibility for the further development of Cytopia's early compounds towards a preclinical candidate compound which is capable of further development into and through clinical trials.
"We are delighted to be embarking on a collaboration of this type with a leading Australian drug development company such as Cytopia," said Tony Evans, CEO of Cancer Therapeutics. "Our company was founded with the vision to aid in the further development of Australian biotechnology industry by applying drug discovery and development capabilities to early research findings and take on projects that are in the high risk category from commercial organizations or academic institutions to unlock their commercial potential."
Cytopia's advanced anti-cancer drug is being tested in four clinical programs covering oral and IV doses in Phase I and Phase II level studies. Trials are advanced for both oral and injectable vascular disrupting agents (VDAs), multiple myeloma and an aggressive brain tumor glioblastoma multiforme (GBM).
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE